119615-63-3 | Olprinone Hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$42.00	$29.00
5mg	98%	in stock	$73.00	$51.00
10mg	98%	in stock	$126.00	$89.00
50mg	98%	in stock	$136.00	$95.00
100mg	98%	in stock	$230.00	$161.00
250mg	98%	in stock	$435.00	$304.00

Description

• Catalog Number: AE11305
• Chemical Name: Olprinone Hydrochloride
• CAS Number: 119615-63-3
• Molecular Formula: C14H11ClN4O
• Molecular Weight: 286.7163
• MDL Number: MFCD00946577
• SMILES: N#Cc1cc(c([nH]c1=O)C)c1ccc2n(c1)ccn2.Cl

Computed Properties

• Complexity: 525
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 1

Upstream Synthesis Route

Olprinone hydrochloride is a potent phosphodiesterase (PDE) inhibitor that is widely utilized in chemical synthesis processes. Specifically, it is frequently employed in the development of novel pharmaceutical compounds due to its ability to modulate cyclic adenosine monophosphate (cAMP) levels in biological systems. By targeting PDE enzymes, Olprinone hydrochloride plays a critical role in regulating cellular signaling pathways involved in various physiological functions, making it a valuable tool in drug discovery and development. Its unique mechanism of action and high selectivity make it a versatile compound for manipulating intracellular cAMP levels, paving the way for the synthesis of innovative molecules with therapeutic potential. Additionally, Olprinone hydrochloride's stability and compatibility with common solvents further enhance its utility as a key reagent in the synthesis of pharmaceutical agents.

Literature

• Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury.

  Advances in experimental medicine and biology 20130101

• Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway.

  American journal of physiology. Lung cellular and molecular physiology 20120701

• Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury.

  Pulmonary pharmacology & therapeutics 20120601

• [Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting].

  Masui. The Japanese journal of anesthesiology 20120601

• Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure.

  Journal of cardiology 20120501

• Controlled reperfusion.

  General thoracic and cardiovascular surgery 20120201

• Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor.

  General thoracic and cardiovascular surgery 20120201

• [Anesthetic management of a patient with pulmonary hypertension due to a large anterior mediastinal tumor anticipated by preoperative computed tomography].

  Masui. The Japanese journal of anesthesiology 20120201

• Neuroprotective effects of olprinone after cerebral ischemia/reperfusion injury in rats.

  Neuroscience letters 20111003

• [Protection from pulmonary apoptosis: a new therapeutic choice for septic acute lung injury].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20111001

• Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice.

  Pharmacological research 20110701

• Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs.

  European journal of anaesthesiology 20110701

• Effect of olprinone, a phosphodiesterase III inhibitor, on balance of cerebral oxygen supply and demand during cardiopulmonary bypass.

  Journal of cardiovascular pharmacology 20110501

• Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts.

  Journal of cardiovascular pharmacology and therapeutics 20110301

• Olprinone, a PDE3 inhibitor, modulates the inflammation associated with myocardial ischemia-reperfusion injury in rats.

  European journal of pharmacology 20110115

• Determination of olprinone in human plasma utilizing liquid chromatography tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20110105

• Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20110101

• Transient cardiac arrest in patient with left ventricular noncompaction (spongiform cardiomyopathy).

  Anesthesia progress 20110101

• Olprinone attenuates the development of ischemia/reperfusion injury of the gut.

  Intensive care medicine 20100701

• Effect of olprinone, a phosphodiesterase III inhibitor, on hepatic ischemia-reperfusion injury in rats.

  Shock (Augusta, Ga.) 20100401

• Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery.

  Journal of anesthesia 20100401

• A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.

  Annals of surgery 20100401

• The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.

  Anesthesia and analgesia 20100301

• Differential vasodilation response to olprinone in rabbit renal and common carotid arteries.

  Journal of anesthesia 20100201

• Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice.

  PloS one 20100101

• Local application of olprinone for promotion of peripheral nerve regeneration.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20091101

• Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.

  Cardiovascular drugs and therapy 20090801

• A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.

  Annals of surgery 20090501

• The phosphodiesterase III inhibitor olprinone inhibits hippocampal glutamate release via a cGMP/PKG pathway.

  Neuroscience letters 20081226

• [The effect of PDEIII inhibitors and colforsin daropate on hypoxic pulmonary vasoconstriction in rabbit lungs].

  Masui. The Japanese journal of anesthesiology 20081101

• [Anesthetic management of coronary artery bypass grafting for unstable angina pectoris in a patient undergoing home oxygen therapy].

  Masui. The Japanese journal of anesthesiology 20080401

• Clinically relevant concentrations of olprinone reverse attenuating effect of propofol on isoproterenol-induced cyclic adenosine monophosphate accumulation in cardiomyocytes.

  Hiroshima journal of medical sciences 20080301

• Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect.

  Pulmonary pharmacology & therapeutics 20080101

• Olprinone decreases elevated concentrations of cytokine-induced neutrophil chemoattractant-1 in septic rats.

  Journal of anesthesia 20080101

• Effects of olprinone on neuromuscular blockade caused by vecuronium.

  Fukushima journal of medical science 20071201

• [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].

  Nihon rinsho. Japanese journal of clinical medicine 20070528

• [How to use PDE III inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20070528

• Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure.

  International journal of urology : official journal of the Japanese Urological Association 20070301

• Selective inhibitors for phosphodiesterase 3 and 4 in antigen-induced increase of cough reflex sensitivity in guinea pigs.

  Pulmonary pharmacology & therapeutics 20070101

• Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion.

  Journal of anesthesia 20070101

• Effects of olprinone on myocardial ischemia-reperfusion injury in dogs.

  The Journal of veterinary medical science 20060801

• Effects of dopamine and olprinone on ventricular energetics in sevoflurane-induced acute left ventricular depression in dogs.

  Journal of cardiothoracic and vascular anesthesia 20060601

• The enhancement of cellular cAMP with olprinone protects autotransplanted rat kidney against cold ischemia-reperfusion injury.

  Transplantation proceedings 20060601

• [Effects of olprinone hydrochloride in patients undergoing off-pump coronary artery bypass grafting].

  Masui. The Japanese journal of anesthesiology 20060201

• The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation.

  Current vascular pharmacology 20060101

• Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.

  European journal of pharmacology 20051228

• Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries.

  Anesthesia and analgesia 20051001

• Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP.

  Shock (Augusta, Ga.) 20050901

• [Successful anesthetic management of three patients with cardiac dysfunction for non-cardiac surgery using olprinone hydrochloride].

  Masui. The Japanese journal of anesthesiology 20050701

• [Anesthetic management for an infant with tetralogy of fallot with absent pulmonary valve].

  Masui. The Japanese journal of anesthesiology 20050201

• Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia.

  Journal of anesthesia 20050101

• The cerebrovascular dilatation effects of olprinone, a phosphodiesterase III inhibitor, in comparison with acetazolamide--a pilot study.

  Clinical neurology and neurosurgery 20040901

• The phosphodiesterase III inhibitor olprinone decreases sensitivity of rat Kupffer cells to endotoxin.

  Alcoholism, clinical and experimental research 20040801

• [Successful management of a patient for cardiac surgery with difficulty in weaning from cardiopulmonary bypass by using both isosorbide dinitrate and olprinone hydrochloride].

  Masui. The Japanese journal of anesthesiology 20040701

• Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery.

  Osaka city medical journal 20040601

• Olprinone improves diaphragmatic contractility and fatigability during abdominal sepsis in a rat model.

  Acta anaesthesiologica Scandinavica 20040501

• [Application of a PDE III inhibitor, olprinone, for fast track pediatric cardiac surgery].

  Masui. The Japanese journal of anesthesiology 20040301

• [Effects of olprinone hydrochloride after coronary artery bypass grafting].

  Masui. The Japanese journal of anesthesiology 20040201

• [Successful anesthetic management of patients with poor ventricular function using the phosphodiesterase III inhibitor, olprinone, during major cardiovascular procedures].

  Masui. The Japanese journal of anesthesiology 20040201

• Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.

  Journal of anesthesia 20040101

• Olprinone for the treatment, but not prevention, of fatigue-induced changes in guinea-pig diaphragmatic contractility.

  Anesthesia and analgesia 20030601

• Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits.

  Anesthesiology 20030601

• [Evaluation of the different doses of olprinone for continuous infusion after cardiopulmonary bypass for coronary artery bypass surgery].

  Masui. The Japanese journal of anesthesiology 20030601

• Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.

  Molecular and cellular biochemistry 20030601

• Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients.

  British journal of clinical pharmacology 20030401

• Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20030201

• Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure.

  Cerebrovascular diseases (Basel, Switzerland) 20030101

• Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.

  Thrombosis research 20030101

• Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.

  Lymphology 20021201

• [Effects of olprinone hydrochloride on intraocular pressure and ocular blood flow in patients after cardiac surgery under cardiopulmonary bypass].

  Masui. The Japanese journal of anesthesiology 20021101

• Inhaled olprinone improves contractility of fatigued canine diaphragm.

  British journal of anaesthesia 20020301

• Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.

  Acta cardiologica 20020201

• Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects.

  Cardiovascular drug reviews 20020101

• Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation.

  The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi 20011001

• Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.

  Circulation 20010807

• A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs.

  Anesthesia and analgesia 20010701

• Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass.

  Acta anaesthesiologica Scandinavica 20010401

• Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient.

  Acta anaesthesiologica Scandinavica 20010401

• Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients.

  Journal of cardiovascular pharmacology 20010401

• The effects of olprinone (a phosphodiesterase III inhibitor) on hepatic vascular bed in a porcine model of endotoxemia.

  Anesthesia and analgesia 20010301

• Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.

  American heart journal 19970301

• [Effects of the new cardiotonic agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscles and sinus nodes].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 19920601